JaLCDOI 10.18926/AMO/30544
フルテキストURL fulltext.pdf
著者 Takahashi, Isao| Hara, Masamichi| Adachi, Tomiro| Takaoka, Kazuko| Sakano, Makoto| Lai, Miinyuh| Kohi, Fumikazu| Yorimitsu, Seiichi| Tokioka, Masaaki| Kitajima, Koichi| Kimura, Ikuro| Sanada, Hiroshi|
抄録 <p>Twelve patients with refractory acute leukemia (7 patients with acute myelocytic leukemia and 5 patients with acute lymphocytic leukemia) were treated with a new anthracycline antibiotic, aclacinomycin-A (ACM). ACM was administrated by intravenous drip infusion at a dose of 20 mg/day for 7 or 14 days and this was repeated after at least 7 days. Four of 12 patients (33.3%) achieved a complete remission; 3 of 7 acute myelocytic leukemia (42.8%) and 1 of 5 acute lymphocytic leukemia (20.0%). The days required for achieving the complete remission ranged from 23 to 78 days (median: 61) and the total doses of ACM used from 180 to 500 mg (median: 310), and the durations of complete remission from 11 to 28+ weeks (median: 21+). The untoward effects on digestive organs, such as nausea, vomiting and anorexia, and hematological toxicities were frequently seen; however, they were controlled by supportive treatment. Alopecia was not observed. Arrythmia was recognized in one patient at the initiation of ACM infusion with complete remission without withdrawal of ACM. These results suggest that ACM is a potentially effective anthracycline antibiotic in the clinical management of acute leukemia.</p>
キーワード aclacinomycin-A leukemia chemotherapy
Amo Type Brief Note
発行日 1980-11
出版物タイトル Acta Medica Okayama
出版者 Okayama University Medical School
開始ページ 349
終了ページ 354
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 6449134
Web of Science KeyUT A1980KT96800007